Literature DB >> 19748234

In vitro susceptibilities of aerobic and facultative anaerobic Gram-negative bacilli from patients with intra-abdominal infections worldwide from 2005-2007: results from the SMART study.

Stephen P Hawser1, Samuel K Bouchillon, Daryl J Hoban, Robert E Badal.   

Abstract

SMART (Study for Monitoring Antimicrobial Resistance Trends) is an ongoing multiyear surveillance study to monitor worldwide antimicrobial resistance trends among aerobic and facultative anaerobic Gram-negative bacilli (GNB) isolated from intra-abdominal infections. During 2005-2007, a total of 255 laboratories from 37 countries in five global regions collected intra-abdominal GNB for antimicrobial susceptibility testing using broth microdilution according to Clinical and Laboratory Standards Institute guidelines. A total of 19703 GNB were isolated from intra-abdominal infections, comprising 5476, 6633 and 7594 GNB were isolated in the years 2005, 2006 and 2007 from 75, 84 and 96 medical centres, respectively. The most frequently isolated organisms were Escherichiacoli, Klebsiella pneumoniae and Enterobacter cloacae, of which 18.0% of E. coli and 26.2% of K. pneumoniae were positive for extended-spectrum beta-lactamase (ESBL). Overall, resistance among GNB increased during 2005-2007 and resistance rates in 2007 were generally higher than data from previous years. Ertapenem and imipenem were the only agents that maintained consistent activity against GNB, including most ESBL-producing isolates.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19748234     DOI: 10.1016/j.ijantimicag.2009.07.013

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  19 in total

1.  Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).

Authors:  Daryl J Hoban; Samuel K Bouchillon; Stephen P Hawser; Robert E Badal; Vincent J Labombardi; Joseph DiPersio
Journal:  Antimicrob Agents Chemother       Date:  2010-05-10       Impact factor: 5.191

2.  Antimicrobial management of intra-abdominal infections: literature's guidelines.

Authors:  Massimo Sartelli; Fausto Catena; Federico Coccolini; Antonio Daniele Pinna
Journal:  World J Gastroenterol       Date:  2012-03-07       Impact factor: 5.742

3.  Colonisation with Escherichia coli resistant to "critically important" antibiotics: a high risk for international travellers.

Authors:  K Kennedy; P Collignon
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-09-12       Impact factor: 3.267

4.  Synthesis and spectrum of the neoglycoside ACHN-490.

Authors:  James B Aggen; Eliana S Armstrong; Adam A Goldblum; Paola Dozzo; Martin S Linsell; Micah J Gliedt; Darin J Hildebrandt; Lee Ann Feeney; Aya Kubo; Rowena D Matias; Sara Lopez; Marcela Gomez; Kenneth B Wlasichuk; Raymond Diokno; George H Miller; Heinz E Moser
Journal:  Antimicrob Agents Chemother       Date:  2010-08-30       Impact factor: 5.191

Review 5.  Infections with extended-spectrum beta-lactamase-producing enterobacteriaceae: changing epidemiology and drug treatment choices.

Authors:  Johann D D Pitout
Journal:  Drugs       Date:  2010-02-12       Impact factor: 9.546

6.  Impact of Gram-negative bacteria on the treatment of venous leg ulcers.

Authors:  Wibke L Engelberg; Martin Dörler; Markus Stücker; Stefanie Reich-Schupke
Journal:  Int Wound J       Date:  2018-08-05       Impact factor: 3.315

7.  A focus on intra-abdominal infections.

Authors:  Massimo Sartelli
Journal:  World J Emerg Surg       Date:  2010-03-19       Impact factor: 5.469

8.  Cost of care and antibiotic prescribing attitudes for community-acquired complicated intra-abdominal infections in Italy: a retrospective study.

Authors:  Lidia Dalfino; Francesco Bruno; Sergio Colizza; Ercole Concia; Andrea Novelli; Fabrizio Rebecchi; Federico Spandonaro; Cristina Alato
Journal:  World J Emerg Surg       Date:  2014-06-20       Impact factor: 5.469

9.  Clinical Efficacy of Ertapenem for Recurrent Cystitis Caused by Multidrug-Resistant Extended-Spectrum β-Lactamase-Producing Escherichia coli in Female Outpatients.

Authors:  Sungmin Song; Chulsung Kim; Donghoon Lim
Journal:  Korean J Urol       Date:  2014-04-10

10.  A Review of Ten Years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011.

Authors:  Ian Morrissey; Meredith Hackel; Robert Badal; Sam Bouchillon; Stephen Hawser; Douglas Biedenbach
Journal:  Pharmaceuticals (Basel)       Date:  2013-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.